Mylan N.V. (MYL) has been under a strong bear grip, hence the stock is down -12.34% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 4.21% in the past 1 week. The stock has risen by 4.76% in the past week indicating that the buyers are active at lower levels, but the stock is down -14.12% in the past 4 weeks.
The stock has recorded a 20-day Moving Average of 2.42% and the 50-Day Moving Average is 7.75%.The 200 Day SMA reached 10.52% Mylan N.V. has dropped 7.15% during the last 3-month period . Year-to-Date the stock performance stands at -22.71%.
Mylan N.V. (MYL) : 7 investment research analysts covering Mylan N.V. (MYL) have an average price target of $56.14 for the near short term. The highest target price given by the Brokerage Firm to the stock is $66 and the lowest target is $48 for the short term. Analysts expect the variance to be within $5.76 of the average price.
For the current week, the company shares have a recommendation consensus of Buy. Mylan N.V. (NASDAQ:MYL): The stock opened at $41.44 and touched an intraday high of $41.86 on Friday. During the day, the stock corrected to an intraday low of $40.93, however, the bulls stepped in and pushed the price higher to close in the green at $41.79 with a gain of 0.72% for the day. The total traded volume for the day was 8,748,894. The stock had closed at $41.79 in the previous trading session.
Mylan N.V., formerly Mylan Inc., is a global pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. Mylan operates in two segments: Generics and Specialty. The Companys generic pharmaceutical business is conducted primarily in the United States and Canada (collectively, North America); Europe, the Middle East, and Africa (collectively, EMEA); and India, Australia, Japan and New Zealand (collectively, Asia Pacific). Its specialty pharmaceutical business is conducted by Mylan Specialty L.P. (Mylan Specialty). The Companys API business is conducted through Mylan Laboratories Limited (Mylan India), which is included within the Asia Pacific region in its Generics Segment. Mylan provides products to customers in approximately 140 countries and territories.